Encore, Myriad Genetics deal

MYGN acquired exclusive worldwide rights from Encore to E-7869 (renamed MPC-7869), a daily oral compound that has completed Phase IIa trials to treat prostate cancer. MYGN said it is elucidating MPC-7...